Halozyme Therapeutics Inc (NASDAQ:HALO)
| 51.67 Delayed Data As of 3:59pm ET |  -0.17 / -0.33%Today’s Change | 32.00 Today|||52-Week Range 59.46 | -9.19% Year-to-Date |
Latest HALO News | Press Releases
| Should iShares Russell 2000 ETF (IWM) Be on Your Investing Radar? Feb 01 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 51.84 |
| Today’s open | 51.41 |
| Day’s range | 51.02 - 51.70 |
| Volume | 22,969 |
| Average volume (3 months) | 1,208,247 |
| Market cap | $7.1B |
Data as of 3:59pm ET, 02/07/2023
Growth & Valuation
| Earnings growth (last year) | +202.13% |
| Earnings growth (this year) | -51.93% |
| Earnings growth (next 5 years) | +29.00% |
| Revenue growth (last year) | +65.67% |
| P/E ratio | 34.9 |
| Price/Sales | 13.32 |
| Price/Book | 36.76 |
Financials
| Next reporting date | February 21, 2023 |
| EPS forecast (this quarter) | $0.30 |
| Annual revenue (last year) | $443.3M |
| Annual profit (last year) | $402.7M |
| Net profit margin | 90.84% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters --, -- |
Forecasts
